NGM·Healthcare·$773M·#120 / 520 in Healthcare
CSTL Castle Biosciences, Inc.
62SOLID
CATEGORY BREAKDOWN
GROWTH6
QUALITY65
STABILITY98
VALUATION94
GOVERNANCE36
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+3.7%
6
> 50% strong
Gross Margin
Revenue retained after direct costs
79.4%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
7.8%
94
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.2x
94
< 3x strong
Rule of 40
Growth rate plus operating margin
-9
13
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
2.4%
19
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+5.0%
70
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CSTL WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CSTL's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.